TCA & MAOI Prescribing Guide for Anxiety

Quick Reference Tool | PsychHQ Source: Module 3, Pharmacotherapy (Lessons 10, 11) | Last Updated: March 2026

---

Who This Tool Is For

TCAs and MAOIs are Stage 2-3 options for treatment-resistant anxiety. They carry risks that SSRIs don't, but for some patients — especially those with treatment-resistant social anxiety or panic disorder — they remain the most effective agents available. This tool covers practical initiation, monitoring, and safety protocols for the agents with the strongest anxiety evidence.

---

Tricyclic Antidepressants

TCA Selection Logic

Clinical Scenario	Agent	Why
OCD or OCD-spectrum anxiety	Clomipramine	Most potent serotonin transporter (SERT) blocker in the TCA class; PET imaging (positron emission tomography — a brain scanning technique) shows 80% SERT blockade at just 10 mg. FDA-approved for OCD (adults, children 10+). Superior to SSRIs in OCD meta-analyses.
Panic disorder	Imipramine	Most panic-specific evidence (Klein 1964 landmark study; Cross-National Collaborative Panic Study, 1,168 patients). Created the modern concept of panic disorder.
Patient who responds to TCA but can't tolerate side effects	Nortriptyline	Secondary amine with 10x NET selectivity over SERT; markedly less sedation, dry mouth, constipation, orthostasis, and weight gain than tertiary amines.
Anxiety + chronic pain	Nortriptyline	Potent noradrenergic mechanism addresses both anxiety and neuropathic/myofascial pain. Lowest weight gain in the TCA class.
Metabolic or weight concerns	Nortriptyline	Lowest weight gain. Avoid amitriptyline (highest weight gain, not preferred for anxiety).

Avoid desipramine for anxiety — highest overdose lethality of any TCA, with minimal anxiety-specific evidence.

TCA Dosing

Agent	Starting Dose	Titration	Target Range	Maximum	TDM Targets
Clomipramine	25 mg at bedtime	25 mg every 4-7 days; avoid >100 mg in first 2 weeks	100-250 mg/day	250 mg/day (adult); 3 mg/kg or 200 mg/day (pediatric OCD)	TDM (therapeutic drug monitoring — blood level checks): clomipramine 70-200 µg/L; desmethylclomipramine 150-300 µg/L; combined 220-500 µg/L; toxicity >900 µg/L
Imipramine	10-25 mg/day (panic patients are sensitive to noradrenergic activation)	10-25 mg every 2-3 days	100-300 mg/day	300 mg/day	110-140 ng/mL (optimal antipanic)
Nortriptyline	25 mg at bedtime	25 mg every 3-7 days	50-150 mg/day (antidepressant); 10-25 mg/day (adjunctive pain)	150 mg/day	50-150 ng/mL

Imipramine dose-response note: Mavissakalian & Perel research showed doses <150 mg/day are often indistinguishable from placebo in panic disorder at the group level — but individual patients do respond at lower doses. Don't change the dose of an individual responder based on aggregate data.

Long-term maintenance: Imipramine discontinuation after 6 months → 37% relapse rate (vs near-zero in the maintenance group). This relapse rate persisted regardless of whether acute-phase treatment lasted 6 or 30 months. Plan for extended maintenance if the patient responds.

Mandatory TCA Safety Monitoring

Overdose lethality — this is not optional counseling:

• Narrow therapeutic index: 10-20 mg/kg is potentially lethal
• A 3-5 day supply can be fatal in intentional overdose
• If active suicidality: prescribe limited quantities (weekly supplies) or arrange family-administered dosing

Cardiac monitoring protocol:

When	What
Before starting	Baseline 12-lead ECG
1-2 weeks after reaching target dose	ECG at steady-state
After any dose increase	Repeat ECG
Immediate discontinuation	QTc (corrected QT interval — a measure of the heart's electrical recovery time) increase ≥60 ms from baseline OR QTc exceeds 500 ms (male) / 510 ms (female)
Stable maintenance	Periodic monitoring (annually at minimum)
Before starting	Correct hypokalemia and hypomagnesemia first

CYP2D6 and pharmacogenomics:

• 5-10% of the population are CYP2D6 poor metabolizers (genetically) — they accumulate TCAs to toxic levels at standard doses
• CPIC (Clinical Pharmacogenetics Implementation Consortium) guideline: 50% starting dose reduction for known poor metabolizers
• Phenoconversion: fluoxetine, paroxetine, duloxetine, and bupropion are strong CYP2D6 inhibitors. Co-prescribing any of these with a TCA functionally converts a normal metabolizer into a poor metabolizer. Reduce TCA dose and order therapeutic drug monitoring (TDM).

Tertiary vs. secondary amine side-effect burden:

Side Effect	Tertiary (clomipramine, imipramine)	Secondary (nortriptyline)
Sedation	Moderate-heavy	Mild
Anticholinergic (dry mouth, constipation, urinary retention, blurred vision)	Moderate-heavy	Mild
Orthostatic hypotension	Moderate	Mild
Weight gain	Moderate-heavy	Lowest in class
Sexual dysfunction	Common	Less common
Cardiac conduction effects	QTc prolongation	QTc prolongation (less)

---

Monoamine Oxidase Inhibitors

The Case for MAOIs in Treatment-Resistant Anxiety

Phenelzine has the largest effect size of any medication studied for social anxiety disorder: 1.02 in the Blanco et al. (2003) meta-analysis, exceeding clonazepam (0.97), gabapentin (0.78), and SSRIs (0.65). Many treatment-resistant anxiety specialists consider an optimized phenelzine trial an essential step before concluding a patient is definitively treatment-resistant, particularly in social anxiety.

Agent Selection

Feature	Phenelzine	Tranylcypromine	Selegiline Transdermal (EMSAM)
Mechanism	Non-selective, irreversible MAO-A + MAO-B inhibitor (blocks both types of the enzyme that breaks down serotonin, norepinephrine, and dopamine); also inhibits GABA-transaminase (the enzyme that degrades GABA, the brain's main calming neurotransmitter — making phenelzine the only antidepressant with dual monoaminergic + GABAergic enhancement)	Non-selective, irreversible MAO-A + MAO-B inhibitor; amphetamine-related structure	Selective MAO-B at 6 mg/24h; non-selective at ≥9 mg
Anxiety evidence	SAD: 64% response (Liebowitz 1992); effect size 1.02 (Blanco 2003); Cochrane NMA: panic effect size 0.45	Limited controlled data; less studied than phenelzine for anxiety	No robust anxiety RCTs (FDA-approved MDD only)
Choose when	Severe anxiety, panic, insomnia predominate	Psychomotor retardation, hypersomnia, leaden paralysis, severe anergia (atypical depression features)	Not recommended for primary anxiety
Profile	Sedating (useful if comorbid insomnia)	Activating (amphetamine-related structure)	6 mg patch: no dietary restrictions; ≥9 mg: full restrictions
Advantages	Unparalleled anxiolytic efficacy; dual mechanism	Less weight gain, less edema, less sexual dysfunction than phenelzine	No dietary restrictions at lowest dose
Key side effects	Orthostatic hypotension (dose-limiting), weight gain, edema, sexual dysfunction (high anorgasmia), pyridoxine depletion	Transient BP surges 1-3 hrs post-dose (distinguish from tyramine crisis)	Application site reactions

Mandatory Washout Before MAOI Initiation

Serotonin syndrome is potentially fatal. No exceptions. No cross-tapering. Ever.

Previous Agent	Washout Period
Most SSRIs, SNRIs	14 days
Fluoxetine	35 days (norfluoxetine has 7-15 day half-life)
Vortioxetine	14-21 days (66-hour half-life)
Clomipramine	14 days
Another MAOI	14 days

Bridging during washout (patient still needs anxiolysis): benzodiazepines, gabapentin, pregabalin, or mirtazapine ≤15 mg are safe options.

Phenelzine Initiation Protocol

Phase	Action
Baseline	Orthostatic BP (sitting/lying → standing, ×2 measurements); baseline weight; consider prophylactic pyridoxine (B6) supplementation (phenelzine depletes pyridoxal phosphate)
Day 1	15 mg daily
Days 3-4	15 mg BID
Days 5-7	15 mg TID (45 mg/day)
By week 2	Target ≥60 mg/day minimum
Weeks 2-6	Hold at 60 mg/day; monitor orthostatic BP; manage side effects
If no response at 6-8 weeks on 60 mg	Escalate by 15 mg/week up to 90 mg/day
Maintenance (once stable)	Cautiously taper to lowest effective dose; some patients maintain on 15 mg/day or every-other-day

Response typically appears at week 4-6 on adequate dosing (≥60 mg/day). Do not declare failure before this point. The Liebowitz 1992 landmark data showed response emerging at 4-6 weeks in patients dosed to 60+ mg/day.

Tranylcypromine Dosing

Start 10 mg/day → usual maintenance 30-60 mg/day → severe refractory cases may exceed 70 mg/day. Same dietary and drug restrictions as phenelzine. Unique AE: transient BP surges 1-3 hours post-dose — distinguish from tyramine crisis (dietary triggers have different timing).

Tyramine Diet — What's Actually Dangerous vs. What's Unnecessarily Restricted

Shulman & Walker systematic review showed traditional MAOI dietary restrictions are excessively broad. The key principle is freshness — tyramine is generated by microbial activity in protein-rich foods over time. Fresh protein is safe; protein left at room temperature for hours becomes dangerous. Cooking doesn't destroy tyramine (heat-stable).

MUST absolutely avoid (>50 mg tyramine threshold for dangerous pressor response):

Category	Specific Foods
Aged cheeses	Cheddar, Stilton, Gruyère, blue cheese, Parmesan
Fermented/cured meats	Dry salami, pepperoni, aged sausages
Fermented beverages	Draft/unpasteurized beer
Yeast extracts	Marmite, Vegemite
Fermented soy	Soy sauce, miso, improperly stored tofu
Fermented vegetables	Sauerkraut, kimchi
Legumes	Broad (fava) beans

SAFE despite traditional prohibition:

Category	Why It's Safe
Fresh meats and fish (consumed promptly)	Tyramine hasn't accumulated
Commercial cheeses (cream, cottage, mozzarella, processed)	Not aged
Pasteurized beer, most wines (moderate quantities)	Pasteurization and production control tyramine levels
Fresh tomatoes, bananas, avocados	Traditional restrictions were based on poor data
Chocolate, coffee	Tyramine content negligible

Begin dietary restrictions with the first MAOI dose. Continue for 14 days after the final dose (time for new MAO enzyme synthesis to restore tyramine metabolism).

Drug Interactions — Two Emergencies

Serotonin syndrome (MAOI + serotonergic agent):

• Exponential serotonin accumulation; potentially fatal
• Absolutely contraindicated: SSRIs, SNRIs, clomipramine, meperidine (Demerol), dextromethorphan (OTC cough), tramadol, MDMA, St. John's Wort, methylene blue, linezolid
• Common real-world near-miss: Patient takes an OTC cough-cold product containing dextromethorphan during a respiratory illness
• Patient counseling: Inform ALL providers (dentists, surgeons, ER physicians); check OTC ingredient labels before purchase; carry a wallet card listing the MAOI and contraindicated drug classes

Hypertensive crisis (MAOI + indirect sympathomimetic):

• Massive norepinephrine release
• Absolutely contraindicated: Pseudoephedrine, phenylephrine, oxymetazoline (nasal sprays), stimulants (amphetamine, methylphenidate)

Safe to co-administer: Antihistamines without serotonergic activity (diphenhydramine, cetirizine); acetaminophen; NSAIDs; most antibiotics (NOT linezolid); morphine, hydromorphone (preferred opioids if analgesia needed). Fentanyl is debated — consult anesthesiologist.

Adverse Effect Management

Side Effect	Prevalence/Impact	Management
Orthostatic hypotension	Most common dose-limiting effect	Slow positional changes; compression stockings; salt and fluid intake; regular home BP monitoring during titration
Weight gain	Often significant with phenelzine	Early dietary counseling; regular weight monitoring; consider tranylcypromine if weight is a primary concern
Sexual dysfunction	Very high anorgasmia/delayed ejaculation rates	Primary driver of non-adherence; discuss openly before starting
Edema	Common with phenelzine	Mild: compression stockings, leg elevation. Severe: may require dose reduction
Sedation	Phenelzine tends sedating	Useful if comorbid insomnia; adjust timing (most or all of dose at bedtime)
Pyridoxine depletion	Can cause paresthesias, numbness, "electric shock" sensations	Supplement with pyridoxine (NOT pyridoxal) form of B6
Insomnia/activation	Common with tranylcypromine	Dose earlier in day; avoid evening doses

Safety Measures — Non-Negotiable

Every MAOI patient needs:

• Wallet card or medical alert listing the MAOI and key contraindicated drug classes (serotonergics, indirect sympathomimetics, meperidine)
• Written dietary guidance (provide the simplified list above, not the traditional exhaustive restrictions that cause unnecessary food avoidance)
• Instruction to inform all providers — matters most in emergency and surgical scenarios where the treating physician may not have access to the medication list
• OTC label-checking habit — specifically cold/cough products containing dextromethorphan and decongestants containing pseudoephedrine or phenylephrine

---

Key References: Liebowitz et al. (1992, SAD landmark RCT, Arch Gen Psychiatry); Blanco et al. (2003, SAD medication meta-analysis); Klein (1964, imipramine-panic discovery); Cross-National Collaborative Panic Study Phase 2 (1,168 patients); Bandelow et al. (2015, NMA, 234 studies); Shulman & Walker (tyramine diet systematic review); CPIC TCA pharmacogenomic guidelines; ASAM 2025 Framework